1. Home
  2. PPYAU vs CADL Comparison

PPYAU vs CADL Comparison

Compare PPYAU & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PPYAU
  • CADL
  • Stock Information
  • Founded
  • PPYAU N/A
  • CADL 1999
  • Country
  • PPYAU
  • CADL United States
  • Employees
  • PPYAU N/A
  • CADL N/A
  • Industry
  • PPYAU
  • CADL Biotechnology: Pharmaceutical Preparations
  • Sector
  • PPYAU
  • CADL Health Care
  • Exchange
  • PPYAU NYSE
  • CADL Nasdaq
  • Market Cap
  • PPYAU N/A
  • CADL 185.2M
  • IPO Year
  • PPYAU N/A
  • CADL 2021
  • Fundamental
  • Price
  • PPYAU $11.69
  • CADL $6.20
  • Analyst Decision
  • PPYAU
  • CADL Strong Buy
  • Analyst Count
  • PPYAU 0
  • CADL 1
  • Target Price
  • PPYAU N/A
  • CADL $11.00
  • AVG Volume (30 Days)
  • PPYAU N/A
  • CADL 590.6K
  • Earning Date
  • PPYAU N/A
  • CADL 08-08-2024
  • Dividend Yield
  • PPYAU N/A
  • CADL N/A
  • EPS Growth
  • PPYAU N/A
  • CADL N/A
  • EPS
  • PPYAU N/A
  • CADL N/A
  • Revenue
  • PPYAU N/A
  • CADL N/A
  • Revenue This Year
  • PPYAU N/A
  • CADL N/A
  • Revenue Next Year
  • PPYAU N/A
  • CADL N/A
  • P/E Ratio
  • PPYAU N/A
  • CADL N/A
  • Revenue Growth
  • PPYAU N/A
  • CADL N/A
  • 52 Week Low
  • PPYAU N/A
  • CADL $0.66
  • 52 Week High
  • PPYAU N/A
  • CADL $14.30
  • Technical
  • Relative Strength Index (RSI)
  • PPYAU 58.50
  • CADL 45.08
  • Support Level
  • PPYAU $11.49
  • CADL $5.75
  • Resistance Level
  • PPYAU $11.80
  • CADL $7.34
  • Average True Range (ATR)
  • PPYAU 0.05
  • CADL 0.50
  • MACD
  • PPYAU -0.02
  • CADL 0.12
  • Stochastic Oscillator
  • PPYAU 91.30
  • CADL 33.47

About PPYAU PAPAYA GROWTH OPPORTUNITY CORP I UNIT 1 CL A COM & 1/2 RED WT EXP31/12/28

Papaya Growth Opportunity Corp I is a blank check company.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: